TenSixteen Bio, which is focused on treating age-related diseases at earlier stages, has raised $40 million in funding. The investors were Foresite Capital and GV.
Source: Press Release
TenSixteen Bio garners $40m
TenSixteen Bio, which is focused on treating age-related diseases at earlier stages, has raised $40 million in funding.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: